×
About 13,108 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,235 results

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host ...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...

Clinical spectrum, outcome and management of immune thrombocytopenia associated with my...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.

Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...

Persistence to hypomethylating agents and clinical and economic outcomes among patients...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.

Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...

Thrombocytopenia and platelet transfusion in myelodysplastic syndromes.
https://doi.org/10.1111/trf.16093
Transfusion Bowen D, Karakantza M

Feb 22nd, 2021 - Thrombocytopenia and platelet transfusion in myelodysplastic syndromes.|2021|Bowen D,Karakantza M,|

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  57 results see all →

Clinicaltrials.gov  6,489 results

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host ...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...

Clinical spectrum, outcome and management of immune thrombocytopenia associated with my...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.

Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...

Persistence to hypomethylating agents and clinical and economic outcomes among patients...
https://doi.org/10.1080/16078454.2021.1889161
Hematology (Amsterdam, Netherlands); Cheng WY, Satija A et. al.

Feb 25th, 2021 - To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). A total of 2,400 adults d...

Transplant May Improve Survival in Older Patients With High-Risk Myelodysplastic Syndrome
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/transplant-may-improve-survival-in-older-patients-with-high-risk-myelodysplastic-syndrome/

Feb 24th, 2021 - Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a...

see more →

News  287 results

Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/944879

Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
https://www.medscape.com/viewarticle/923569

Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...

see more →

Patient Education  9 results see all →